Deferasirox Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 125 mg, 250 mg, and 500 mg
Reference Brands: Exjade(Dispersible tablets);Jadenu (Film-coated Tablet)s
Category:
Blood Disorder
Deferasirox binds to excess iron in the bloodstream, forming a complex that is excreted primarily via feces. It effectively reduces iron overload in patients with chronic transfusions. Benefits include convenient once-daily oral dosing, improved patient compliance, shortened treatment duration, and prevention of organ damage caused by iron accumulation.
Deferasirox tablets is available in Tablet
and strengths such as 125 mg, 250 mg, and 500 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Deferasirox tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Deferasirox tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Deferasirox tablets, marketed as Exjade and Jadenu, are approved in the US by the FDA and in the EU via EMA for treating chronic iron overload in transfusion-dependent patients. Regulatory approval requires a comprehensive dossier including clinical data, manufacturing quality, safety, efficacy, and pharmacovigilance plans. In the US, FDA review involves detailed assessment, while EMA approval follows strict regional guidelines, ensuring consistent quality standards. For expert guidance on dossier preparation, regulatory pathways, and successful market access, visit PharmaTradz. Compliance with regional regulations is essential for the safe, effective, and timely approval of deferasirox tablets worldwide, supporting optimal patient management.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing